This video features a presentation at the Best of Lung 2023 conference. Jaime Schneider, MD discusses the latest advancements in targeted therapies for lung cancer. They highlight the significant burden of lung cancer, with 230,000 new cases and over 150,000 deaths annually in the US. The focus is on non-small cell lung cancer (NSCLC), which constitutes 85% of cases. The presentation covers the evolution from chemotherapy to targeted therapies and immunotherapies, emphasizing the importance of molecular profiling for treatment. Key targeted therapies and their impact on patient outcomes, including EGFR and ALK inhibitors, are reviewed, showcasing improved survival and quality of life.